06-05-21 - Biomedical Sciences

Regulatory Affairs Manager 50-80 %

The Wyss Zurich project MUVON is developing a low-risk, minimally invasive treatment that uses the patient's own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle, thus potentially providing a cure for stress urinary incontinence, as first target indication. Currently being at the end of Phase1 clinical trial, the MUVON project has been supported by Wyss Zurich and will now proceed with the clinical and commercial development of their therapy, evaluating the efficacy of the approach during a Phase 2 clinical trial and undertaking all the required activities for a regulatory approval. To expand the team, the project is now looking for a motivated Regulatory Affairs Manager (50-80%).

read more